Attracting, developing, and retaining talented workers – both Saudi and foreign – is perhaps the key sticking point to Saudi Arabia achieving its ambitious transformation targets. Thus far this has…
Despite an adverse funding panorama and looming geopolitical tensions, Chinese biotech is still thriving. Companies originating in China are advancing promising pipelines, going public, looking beyond China’s borders with a…
Writing in the July 2024 edition of DIA’s Global Forum magazine Mingcan DU and Fengyun (Vicky) HAN of Johnson & Johnson Global Regulatory Policy and Intelligence look back at the…
The IFPMA’s Sarah Adam, writing in the July 2024 edition of DIA’s Global Forum magazine, looks back on an insightful discussion on the progress towards an African Medicines Agency at…
The timely and equitable provision of treatment and prevention tools is just one part of the ongoing fight against HIV. Local, national, regional, and international authorities – many of which…
Several major scientific breakthroughs in HIV prevention and treatment in the past 40 years have successfully transformed HIV from a near-certain ‘death sentence’ to a manageable chronic disease where many…
In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step…
This year has seen no less than five GM changes at international pharma companies’ Mexican affiliates. Pfizer, MSD, Roche, Sanofi and Gilead have all taken on new local leadership. In…
The newly elected UK government’s Secretary of State for Health and Social Care Wes Streeting has a full plate of challenges ahead. Britain’s National Health Service (NHS) is plagued with…
Some of the biggest stories coming out of Spain’s pharma industry, including Brookfield’s bid for a troubled Grifols; Esteve’s Spanish plant expansion; Rovi’s offers for a potential buyout of its…
Poised to overtake Japan and become the world’s fourth-largest economy by 2025 according to the latest International Monetary Fund estimates and now registering heady year-on-year growth rates exceeding eight percent,…
As pharma navigates issues ranging from the US Inflation Reduction Act to new EU pharmaceutical legislation, and the impact of global unrest on supply chains, the industry is experiencing other…
See our Cookie Privacy Policy Here
